120 related articles for article (PubMed ID: 18593334)
1. Quantification of neutralizing antibodies to human type I interferons using division-arrested frozen cells carrying an interferon-regulated reporter-gene.
Lallemand C; Meritet JF; Erickson R; Grossberg SE; Roullet E; Lyon-Caen O; Lebon P; Tovey MG
J Interferon Cytokine Res; 2008 Jun; 28(6):393-404. PubMed ID: 18593334
[TBL] [Abstract][Full Text] [Related]
2. Measurement of neutralising antibodies to type I interferons by gene expression assays specific for type 1 interferon-inducible 6-16 mRNA.
Moore M; Meager A; Wadhwa M; Burns C
J Pharm Biomed Anal; 2009 Feb; 49(2):534-9. PubMed ID: 19097723
[TBL] [Abstract][Full Text] [Related]
3. Quantification of different human alpha interferon subtypes and pegylated interferon activities by measuring MxA promoter activation.
François C; Bernard I; Castelain S; Charleston B; Fray MD; Capiod JC; Duverlie G
Antimicrob Agents Chemother; 2005 Sep; 49(9):3770-5. PubMed ID: 16127052
[TBL] [Abstract][Full Text] [Related]
4. Validation of a HeLa Mx2/Luc reporter cell line for the quantification of human type I interferons.
Seo YJ; Kim GH; Kwak HJ; Nam JS; Lee HJ; Suh SK; Baek KM; Sohn YW; Hong SH
Pharmacology; 2009; 84(3):135-44. PubMed ID: 19684437
[TBL] [Abstract][Full Text] [Related]
5. Cell-based reporter gene assay for therapy-induced neutralizing antibodies to interferon-beta in multiple sclerosis.
Martins TB; Rose JW; Gardiner GL; Kusukawa N; Husebye D; Hill HR
J Interferon Cytokine Res; 2013 Feb; 33(2):52-7. PubMed ID: 23153300
[TBL] [Abstract][Full Text] [Related]
6. Measured neutralizing titers of IFN-beta neutralizing antibodies (NAbs) can depend on the preparations of IFN-beta used in the assay.
Files JG; Hargrove D; Delute L; Cantillon M
J Interferon Cytokine Res; 2007 Aug; 27(8):637-42. PubMed ID: 17784815
[TBL] [Abstract][Full Text] [Related]
7. Development of neutralizing interferon antibodies after treatment with recombinant interferon-alpha 2b in patients with malignant carcinoid tumors.
Oberg K; Alm GV
J Interferon Res; 1989 Sep; 9 Suppl 1():S45-9. PubMed ID: 2809277
[TBL] [Abstract][Full Text] [Related]
8. Antibodies to interferon-alpha 2 in patients treated with interferon-alpha 2 for hairy cell leukemia.
Bekisz JB; zur Nedden DL; Enterline JC; Zoon KC
J Interferon Res; 1989 Sep; 9 Suppl 1():S1-7. PubMed ID: 2809275
[TBL] [Abstract][Full Text] [Related]
9. A novel cell-based assay for measuring neutralizing autoantibodies against type I interferons in patients with autoimmune polyendocrine syndrome type 1.
Breivik L; Oftedal BE; Bøe Wolff AS; Bratland E; Orlova EM; Husebye ES
Clin Immunol; 2014 Jul; 153(1):220-7. PubMed ID: 24792136
[TBL] [Abstract][Full Text] [Related]
10. Anti-interferon-α neutralizing antibody is associated with nonresponse to pegylated interferon-α plus ribavirin in chronic hepatitis C.
Matsuda F; Torii Y; Enomoto H; Kuga C; Aizawa N; Iwata Y; Saito M; Imanishi H; Shimomura S; Nakamura H; Tanaka H; Iijima H; Tsutsui H; Tanaka Y; Nishiguchi S
J Viral Hepat; 2012 Oct; 19(10):694-703. PubMed ID: 22967100
[TBL] [Abstract][Full Text] [Related]
11. Pegasys (Hoffmann-La Roche).
Barnard DL
Curr Opin Investig Drugs; 2001 Nov; 2(11):1530-8. PubMed ID: 11763153
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies to interferon-alpha: relative frequency in patients treated with different interferon preparations.
Antonelli G; Currenti M; Turriziani O; Dianzani F
J Infect Dis; 1991 Apr; 163(4):882-5. PubMed ID: 1901335
[TBL] [Abstract][Full Text] [Related]
13. Incidence of autoantibodies against type I and type II interferons in a cohort of systemic lupus erythematosus patients in Slovakia.
Slavikova M; Schmeisser H; Kontsekova E; Mateicka F; Borecky L; Kontsek P
J Interferon Cytokine Res; 2003 Mar; 23(3):143-7. PubMed ID: 12716486
[TBL] [Abstract][Full Text] [Related]
14. Sensitive antiproliferative neutralization assay for the detection of neutralizing IFN-alpha and IFN-beta antibodies.
Prümmer O; Streichan U; Heimpel H; Porzsolt F
J Immunol Methods; 1994 May; 171(1):45-53. PubMed ID: 8176238
[TBL] [Abstract][Full Text] [Related]
15. Development and characterization of a non-cell-based assay to assess the presence of neutralizing antibodies to interferon-beta in clinical samples.
Cludts I; Meager A; Thorpe R; Wadhwa M
J Immunol Methods; 2013 Sep; 395(1-2):37-44. PubMed ID: 23831137
[TBL] [Abstract][Full Text] [Related]
16. Anti-Interferon Alpha Antibodies in Patients with High-Risk BCR/ABL-Negative Myeloproliferative Neoplasms Treated with Recombinant Human Interferon-α.
Aruna ; Li L
Med Sci Monit; 2018 Apr; 24():2302-2309. PubMed ID: 29693647
[TBL] [Abstract][Full Text] [Related]
17. IFN-alpha antibodies in patients with age-related macular degeneration treated with recombinant human IFN-alpha2a.
Ross C; Engler CB; Sander B; Bendtzen K
J Interferon Cytokine Res; 2002 Apr; 22(4):421-6. PubMed ID: 12034024
[TBL] [Abstract][Full Text] [Related]
18. WISH cell line: from the antiviral system to a novel reporter gene assay to test the potency of human IFN-α and IFN-β.
Bürgi Mde L; Prieto C; Etcheverrigaray M; Kratje R; Oggero M; Bollati-Fogolín M
J Immunol Methods; 2012 Jul; 381(1-2):70-4. PubMed ID: 22549076
[TBL] [Abstract][Full Text] [Related]
19. Neutralizing antibodies to interferon.
Noronha A
Neurology; 2007 Jun; 68(24 Suppl 4):S16-22. PubMed ID: 17562846
[TBL] [Abstract][Full Text] [Related]
20. Anti-interferon antibodies to interferon-alpha 2b: results of comparative assays and clinical perspective.
Spiegel RJ; Jacobs SL; Treuhaft MW
J Interferon Res; 1989 Sep; 9 Suppl 1():S17-24. PubMed ID: 2553829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
